Surface Modification Technology Platform

Endexo

Endexo Logo

ANTI-THROMBOGENIC ADDITIVES

Low molecular weight additives that provide passive surface modification for blood contacting medical devices

Endexo™ surface modifying macromolecules enhance the biocompatibility of medical devices that come in contact with blood or tissue. They are low molecular weight fluoro-oligomeric additives that bloom to the top few nanometers of the device surface, during the manufacturing process.

Therefore, the surface properties are that of a fluorinated surface, capable of inhibiting platelet activation and suppressing protein procoagulant conformation.  Altogether, the effect is reduced thrombosis which both increases device functionality as well as reducing thrombus related complications such as DVTs (deep vein thrombosis) in catheter based applications.

Endexo™ platform technology has broad applicability.  With 70+ formulations, the Endexo technology can be used with a variety of base polymers (including polyurethane, polysulfone, PVC, polypropylene, silicone) and manufacturing techniques (such as melt extrusion, solution spinning, injection molding). The Endexo™ molecules become an integral part of the base material and provides extended efficacy of treatment compared to traditional coatings.

ADVANTAGES

DEVICE
  • Passive surface modification
  • Permanent presence on all device surfaces
  • No impact on device functionality
MANUFACTURING
  • No change to existing manufacturing processes
  • Compatible with a wide range of base polymers
  • Low cost technology

Play Video

The video illustrates the simple process of using the Endexo™ technology. The Endexo™ SMMs (surface modifying molecules) are added to the base polymer and compounded prior to the normal manufacturing process.

COMMERCIAL APPLICATION CASE STUDY:

BIOFLO™ WITH ENDEXO FROM ANGIODYNAMICS

CLINICAL DATA

Average reduction across 8500 BioFlo PICCs studied:
As reported by AngioDynamics

Clinical Data

COMMERCIAL TRACTION

65% Bioflo Growth rate
600k Bioflo Catheters placed
3700+ GPO Hospitals eligible to buy bioflo

endexo case study

SOURCE: ANGO FDA Approval documents;
Needham & Company 14th Annual Healthcare Conference, April 14,2015

Play Video

BioFlo PICC Patient Story

Learn how the BioFlo PICC with Endexo technology offered a solution to this patient's PICC line infections

FUTURE OPPORTUNITIES

Blood Contacting Devices

Dialyzers (licensed exclusively to Fresenius Medical Care)

Dialysis blood lines (licensed exclusively to Fresenius Medical Care)

Non-dialysis blood lines

Short-term catheters

Perfusion

Apheresis

Diagnostics

Medical Device Anti-fouling

Reduced protein adhesion

Reduced bacterial adhesion

Powered by Innovasium